Netrin-1 expression and targeting in multiple myeloma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Deleted in colorectal cancer (DCC) and uncoordinated-5 (UNC5) receptors are dependence receptors involved in tumor progression in solid tumors.
• Netrin-1, their ligand, is a potential therapeutic target, but its role in hematological malignancies is underexplored.
• Understanding netrin-1 signaling in multiple myeloma is crucial for developing novel treatment strategies.

Purpose of the Study:

• To investigate the expression of netrin-1 and its receptors (DCC, UNC5H2(B)) in multiple myeloma.
• To evaluate the anti-myeloma activity of a novel anti-netrin-1 agent (NP137) in vitro and in vivo.
• To explore netrin-1 signaling as a potential therapeutic target in multiple myeloma.

Main Methods:

• Screening of human myeloma cell lines and patient bone marrow samples for netrin-1 and its receptors.
• Immunohistochemistry and flow cytometry to confirm expression.
• In vitro assays assessing NP137's effect on myeloma cell lines, alone and in combination with bortezomib and dexamethasone.
• In vivo studies using SCID mice with human myeloma tumors.
• Ex vivo analysis of bone marrow aspirates from patients treated with NP137.

Main Results:

• Heterogeneous expression of netrin-1, DCC, and UNC5H2(B) was observed in myeloma cell lines and patient samples.
• NP137 did not induce apoptosis independently but enhanced the cytotoxicity of bortezomib and dexamethasone in vitro.
• NP137 treatment reduced tumor size in a mouse model of multiple myeloma.
• Ex vivo, NP137 decreased plasma cell percentages in a subset of patient samples.

Conclusions:

• Netrin-1 and its receptors are expressed in multiple myeloma, suggesting a role for this signaling pathway.
• The anti-netrin-1 agent NP137 shows potential as an adjunct therapy, enhancing existing treatments.
• Netrin-1 signaling represents a promising novel therapeutic target for multiple myeloma.